Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

MDS Nordion starts production of Rubidium-82 generators for Bracco Diagnostics

MDS Nordion : 11 June, 2009  (Company News)
MDS Nordion is commencing the manufacture of CardioGen-82 (Rubidium-82 generators), for Bracco Diagnostics (part of Bracco Group), one of the world's leading companies in the imaging agent business.
MDS Nordion has designed and built a dedicated manufacturing suite within its world-class, US Food and Drug Administration (FDA)-approved, Good Manufacturing Practices (GMP)-compliant production facility in Ottawa.

CardioGen-82, the only generator-based, cardiac Positron Emission Tomography (PET) perfusion imaging agent approved by the FDA, produces Rubidium-82, using a specialised generator technology. Once administered to the patient, Rubidium-82 is used as a PET imaging tracer for perfusion studies of the heart to examine blood flow through heart vessels. PET is a sensitive medical imaging technique that produces a three-dimensional image of the functioning heart, allowing the cardiologist to identify regions of the heart muscle receiving poor blood flow.

'There is growing interest in advanced molecular imaging technologies to help better diagnose and treat disease,' said Steve West, President of MDS Nordion. 'MDS Nordion provides a full spectrum of services for the development and commercialization of novel radiopharmaceuticals. For more than 10 years, companies like Bracco have been relying on our proven track record for innovative solutions, quality, and reliability that make MDS Nordion the partner of choice.'

A 2007 Frost and Sullivan report entitled US PET and PET-CT (Computerised Tomography) Imaging Equipment Markets indicated that use of PET imaging as a diagnostic tool is on the rise. For the period 2007-2014, the report projects a total compounded annual growth rate of 17.3 percent for PET and PET-CT.

'This is an important milestone in the development of Bracco's innovative cardiac imaging technology and the new MDS facility provides Bracco with a world-class manufacturing capability with significant capacity for future expansion to meet anticipated market growth,' said Carlo Medici, President and Chief Executive Officer of Bracco Diagnostics. 'MDS Nordion's unique expertise in the development and manufacture of radiopharmaceuticals, along with its specialised facilities, made them an obvious choice when Bracco looked to expand its CardioGen-82 production capacity.'
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo